Provided by Chambers
Cooley fields a well-respected team that covers US and Hong Kong listings, private placements, and secondary and follow-on offerings. Its team acts for issuers, sponsors and underwriters and is particularly renowned for handling IPOs in the tech, healthtech and life sciences sectors.
Cooley advised Morgan Stanley, Jefferies and CITICS/CLSA as the underwriters of Duality Biologics on its HKD1.64 billion IPO.
Provided by Chambers
Cooley has a very good team structure, with a well-established team with capabilities from both the US and HK sides, who can solve our problems no matter when and how we raise them.
Cooley's strengths in HK IPOs include deep cross-border expertise and seamless coordination between jurisdictions, as well as a tech-savvy focus and commercial pragmatism.
They have great communication with the sponsors and gave us very clear instructions and helpful advice.
Cooley has a very good team structure, with a well-established team with capabilities from both the US and HK sides, who can solve our problems no matter when and how we raise them.
Cooley's strengths in HK IPOs include deep cross-border expertise and seamless coordination between jurisdictions, as well as a tech-savvy focus and commercial pragmatism.
They have great communication with the sponsors and gave us very clear instructions and helpful advice.
Provided by Chambers
Michael Yu is frequently mandated on IPOs, secondary offerings and placements in the tech and biotech sectors, handling both 18A and 18C listings.
He is very professional and can help us negotiate with the Hong Kong exchange and he knows many senior people there.
He is flexible and can understand the client's needs.
Will Cai has a strong track record handling IPOs in the technology, biotech, logistics and heavy industry sectors.
I respect him a lot. He's a notable name who is very good.